fda restrictions on compounding bpc-157 Regulatory Alert: FDA's April 2026 Update and GHK-Cu – Holt Law FDA reviewers urge 'no' on

restrictions included: English- or French-language publications

Always consult a qualified healthcare provider before making decisions about your health

Further studies will be required before this approach can be offered as a first-line medical treatment

As with any injectable treatment, there is a risk of infection at the administration site

Procedure and Medication The procedure involves injecting a local anesthetic and corticosteroid into the facet joint

The Food and Drug Administration (FDA) classifies BPC-157 strictly as a research compound, prohibiting the product's use as an approved therapeutic or dietary supplement in human applications